Abstract
The pharmacokinetics of 5-fluorouracil (5FU) were studied in vivo in patients with discrete tumors and in rabbits bearing VX2 tumors by using 19F NMR spectroscopy. The human studies were conducted in a 1.5-T Magnetom magnetic resonance imager (Siemens), and the rabbit studies were conducted in a 4.7-T GE/Nicolet 33-cm bore magnet. Free 5FU was detected in the tumors of four of the six patients and in all VX2 tumors but not in normal rabbit tissues. No other metabolites were seen in these tumors, contrary to the extensive catabolism we had previously documented using 19F NMR spectroscopy in both human and animal livers. The tumor pool of free 5FU in those human tumors that trapped 5FU was determined to have a half-life of 0.4-2.1 hr, much longer than expected and significantly longer than the half-life of 5FU in blood (5-15 min), whereas the half-life of trapped 5FU in the VX2 tumors ranged from 1.05 to 1.22 hr. In this initial experience, patient response to chemotherapy may correlate with extent of trapping free 5FU in the human tumors. These studies document that NMR spectroscopy is clinically feasible in vivo, allows noninvasive pharmacokinetic analyses at a drug-target tissue in real time, and may produce therapeutically important information at the time of drug administration. Demonstration of the trapping of 5FU in tumors provides both a model for studying metabolic modulation in experimental tumors (in animals) and a method for testing modulation strategies clinically (in patients).
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Balis F. M., Holcenberg J. S., Bleyer W. A. Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet. 1983 May-Jun;8(3):202–232. doi: 10.2165/00003088-198308030-00002. [DOI] [PubMed] [Google Scholar]
- Bernadou J., Armand J. P., Lopez A., Malet-Martino M. C., Martino R. Complete urinary excretion profile of 5-fluorouracil during a six-day chemotherapeutic schedule, as resolved by 19F nuclear magnetic resonance. Clin Chem. 1985 Jun;31(6):846–848. [PubMed] [Google Scholar]
- Brechner R. R., D'Argenio D. Z., Dahalan R., Wolf W. Noninvasive estimation of bound and mobile platinum compounds in the kidney using a radiopharmacokinetic model. J Pharm Sci. 1986 Sep;75(9):873–877. doi: 10.1002/jps.2600750909. [DOI] [PubMed] [Google Scholar]
- Collins J. M., Dedrick R. L., King F. G., Speyer J. L., Myers C. E. Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther. 1980 Aug;28(2):235–246. doi: 10.1038/clpt.1980.156. [DOI] [PubMed] [Google Scholar]
- Kar R., Cohen R. A., Terem T. M., Nahabedian M. Y., Wile A. G. Pharmacokinetics of 5-fluorouracil in rabbits in experimental regional chemotherapy. Cancer Res. 1986 Sep;46(9):4491–4495. [PubMed] [Google Scholar]
- Sobrero A. F., Moir R. D., Bertino J. R., Handschumacher R. E. Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine in the HCT-8 human carcinoma line. Cancer Res. 1985 Jul;45(7):3155–3160. [PubMed] [Google Scholar]
- Stevens A. N., Morris P. G., Iles R. A., Sheldon P. W., Griffiths J. R. 5-fluorouracil metabolism monitored in vivo by 19F NMR. Br J Cancer. 1984 Jul;50(1):113–117. doi: 10.1038/bjc.1984.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wolf W., Albright M. J., Silver M. S., Weber H., Reichardt U., Sauer R. Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. Magn Reson Imaging. 1987;5(3):165–169. doi: 10.1016/0730-725x(87)90016-6. [DOI] [PubMed] [Google Scholar]
- Yamamoto S., Kawasaki T. Active transport of 5-fluorouracil and its energy coupling in Ehrlich ascites tumor cells. J Biochem. 1981 Sep;90(3):635–642. doi: 10.1093/oxfordjournals.jbchem.a133517. [DOI] [PubMed] [Google Scholar]